Sign in
Taking peopleNo phase

A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile

Key facts

Who runs it
Miguel O'Ryan Gallardo
Where
Chile3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
500 people, planned
Started
2 Aug 2022
Expected to end
Aug 2027
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Lansoprazole
  • Amoxicillin
  • Clarithromycin
  • Metronidazole
Record updated
17 December 2025

Who can take part

Age
14 years to 18 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Healthy teenagers 14-18 years of age from Colina, Temuco or Coyhaique
  • At least one responsible adult family member accessible for phone contact
  • Persistent H. pylori infection determined by at least 2 positive UBT tests in a 3 months period (except for Non-infected Controls)

Who cannot take part

  • Prior eradication therapy
  • Antimicrobial course received during the previous month (at least 3 days of treatment at appropriate dosing, children meeting this criteria can be included at a later stage)
  • Use of immunosuppressive or biologic drugs
  • Known allergy to any of the antimicrobials used in the trial protocol (except for Non-infected Controls)
  • Teenagers not consenting to treatment will be invited to continue as non-treated controls
  • Signs/symptoms compatible with organic abdominal pain according to Rome IV criteria: persistent right upper or right lower quadrant pain, dysphagia, odynophagia, persistent vomiting, gastrointestinal blood loss, involuntary weight loss, deceleration of linear growth, delayed puberty
  • Pregnancy
  • Children deemed "not healthy" after review of the questionnaire by study physician

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Helicobacter pylori infection

This trial is currently available in Chile.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gastric cancer remains a global health problem, and Chile has one of the highest GC mortality rates in the region. Helicobacter pylori (H. pylori) infection is ubiquitous in Chilean adults, and it constitutes the main cause of GC worldwide. A long-term process occurs from premalignant lesions to carcinoma. H. pylori eradication during early stages of disease significantly impacts outcomes, favoring survival, disease reversal and molecular changes, which supports a "screen and treat" strategy in asymptomatic populations in areas with intermediate-to-high GC prevalence. The Investigators' previous research has shown that H. pylori infection is acquired in early childhood with low rates of spontaneous eradication. A pilot treatment study in a subset of school-aged asymptomatic children showed a high rate of successful eradication (>95%), good tolerance, and was associated with a decrease in serum biomarkers of gastric damage (pepsinogen I and II). Based on the results of these studies, the Investigators propose to advance towards the next stage of this research process: a "screen and treat" strategy. The current trial starts with a Screening phase testing up to 1000 asymptomatic adolescents 14-18 years of age from 3 cities of Chile (Colina, Temuco and Coyhaique), to find a total of 210 persistently-infected participants. Persistently-infected adolescents will be included in a Second phase of this trial: A randomized, case-control, non-blinded study to either receive antimicrobial treatment targeting H. pylori eradication (cases) or no treatment (controls). A subset of 60 non-infected adolescents will be followed-up in matched times. This aims to provide evidence on the effect of treatment on clinical outcomes and serum biomarkers related to gastric damage, as well as composition and antimicrobial resistance of gut microbiota. The Investigators expect that eradication therapy will be successful in >90% of persistently infected adolescents, with reinfection rates not surpassing 15% in a 2-3 year period, and to be associated with a decrease in clinical findings indicative of gastric disease, and a decrease in serum biomarker indicative of "gastric damage".

The 3 groups in the trial

  • CasesTreatment being tested

    140 children with H. pylori-persistent infection, who will receive eradication therapy

    Treatment: Lansoprazole, Amoxicillin, Clarithromycin, and Metronidazole

  • ControlsNo study treatment, for comparison

    70 children with H. pylori-persistent infection, who will not receive eradication therapy

  • Non infected ControlsNo study treatment, for comparison

    60 adolescents with no H. pylori infection, they will not receive eradication therapy

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized "Screen and Treat" Helicobacter Pylori Eradication Trial in 14-18 Years Old Adolescents Residing in Three Regions of Chile: Effectiveness and Microbiological-host Implications
Criteria questions
Built from NCT05926804, who can take part
Publications
Record updated
17 December 2025